Bingo Mwolo est le coureur à pied le plus rapide de Nairobi... et sans doute du monde. À quinze ans, il en paraît à peine dix et c'est grâce à cela et à sa rapidité qu'il parvient à ne pas se faire remarquer par les policiers corrompus lorsqu'il court livrer leurs doses de drogue aux clients blancs de son boss. Après avoir été le témoin du meurtre du plus important dealer de Nairobi, la vie pourtant déjà risquée de Bingo devient bien plus dangereuse encore. Pris au beau milieu d'une lutte entre parrains de la pègre, il trouve refuge dans un étrange orphelinat dirigé par un prêtre qui ne fait pas que propager la parole de Dieu mais est également à la tête d'un commerce lucratif et peu honnête. Et puis, il y a aussi Thomas Hunsa, un peintre, client de Bingo, qu'il croit être son meilleur atout pour échapper à la misère si il arrive à persuader le monde qu'il n'est pas seulement le coureur le plus rapide, mais aussi le meilleur marchand d'art de Nairobi... À l'instar des Cerfs-volants de Kaboul de Khaled Hosseini ou du Tigre blanc d'Aravind Adiga, Bingo's run est un roman attachant qui entraîne le lecteur à la découverte d'une culture étrangère bien peu connue. C'est aussi une histoire pleine de rebondissements inattendus, contée avec tendresse, celle d'un jeune héros qui tente de survivre dans une Nairobi violente et bouillonnante.

Dacmar est un guide pratique, clair et extrêmement rapide destiné aux entrepreneurs en biotechnologie, aux créateurs de start-ups biotech et à tous ceux qui souhaitent transformer des innovations scientifiques en solutions à fort impact. Vous découvrirez en 6 étapes clés comment réussir sa start-up en biotechnologie. Vous rêvez de lancer votre start-up biotech ? Si votre objectif est de développer des médicaments innovants et de bâtir une entreprise solide, découvrez l'avantage Dacmar. Chaque chapitre se lit en cinq minutes : en moins de deux heures, vous maîtriserez les fondations indispensables pour créer et structurer une biotech performante. À la fin du parcours Dacmar, vous serez prêt à réussir : acquisition, entrée en bourse ou croissance indépendante - votre start-up aura le potentiel de s'imposer. Grâce à votre vision entrepreneuriale, des millions de patients pourront bénéficier de nouveaux traitements. L'avantage Dacmar vous guide, étape par étape, vers un succès durable.?A PROPOS DE L'AUTEUR?James A. Levine, président de la Fondation Ipsen, est médecin et chercheur de renommée internationale. Fort de plus de trente ans d'expérience, notamment à la Mayo Clinic, il dirige depuis six ans une organisation engagée dans l'innovation biotechnologique au service des maladies rares. Auteur de plus de 200 publications scientifiques - dont six parues dans Science et Nature - il a également contribué aux principales revues médicales telles que le New England Journal of Medicine, The Lancet et JAMA. Il a rédigé quatre ouvrages traduits en 19 langues et publiés dans 37 pays. Il est également formé à l'entrepreneuriat à la Harvard Business School. Expert des technologies portables, de l'analyse de données et de l'innovation médicale, il détient plus de 100 brevets et marques déposées. Il a cofondé 35 entreprises et a été distingué comme innovateur de l'année dans l'État du Minnesota, à la Foire mondiale du commerce et par la NASA. Sous les marques NEAT de la Mayo Clinic, son équipe a déployé des solutions de santé évolutives auprès de 72 entreprises américaines. Ses travaux portent sur le développement biotechnologique, les modèles économiques durables et la création d'opportunités dans des régions sous-desservies aux États-Unis, en France et dans plusieurs pays à revenu faible ou intermédiaire (RDC, Côte d'Ivoire, Afghanistan, Jamaïque, Asie, Kenya, Inde). Conseiller auprès de la présidence des États-Unis, du Département d'État, de l'armée américaine et d'organisations internationales, James a reçu la médaille présidentielle en 2018 pour son engagement social. Aujourd'hui, 300 millions de personnes vivent avec des maladies rares sans traitement efficace. Pour faire émerger des solutions durables, il est crucial d'optimiser l'utilisation du capital, de structurer les entreprises biotech avec rigueur et de maximiser leur impact tout en réduisant la souffrance humaine.

DACMAR is a FAST BUSINESS GUIDE for newbie biotech entrepreneurs. GIVE ME 5 MINUTES: If you know nothing about modern biotech business lingo, grab this book and read the LEARNING BOXES. In 5 minutes, you'll know DACMAR - you'll know enough! If you WANT TO BUILD a SUCCESSFUL biotech start-up that delivers new medicines, read the DACMAR ADVANTAGE. Each chapter will take you 5 minutes. By the time you are finished in less than 2 hours, you'll have the DACMAR ADVANTGE. DACMAR is the basic business building blocks for a biotech start-up. At the conclusion of the DACMAR ADVANTAGE, I take you to the WIN! Your start-up flourishes: you are acquired or go public. Through your entrepreneurial genius, millions of patients will be saved. The DACMAR ADVANTAGE will help you win. ABOUT THE AUTHOR James A. Levine - Dr. Levine, President Fondation Ipsen, has three decades of experience in the healthcare sector principally at Mayo Clinic. For the last 6 years he has been President of Fondation Ipsen, an international science foundation focused on biotech innovation in Rare Diseases. A physician and scientist, James has published more than 200 articles, six papers in Science and Nature plus articles in journals such as, the New England Journal of Medicine, Lancet and JAMA. He has written four books published in 19 languages in 37 countries. His business training, focused on entrepreneurship, was from Harvard Business School. With a background in wearable technologies, data gathering and data analytics, and with more than 100 patents and trademarks, Levine helped found 35 companies. He was the Innovator of the Year in the state of Minnesota, the World Trade Fair and NASA. Under the Mayo Clinic NEAT Trademarks, Levine's team delivered scalable health solutions to 72 US corporations. A great deal of James' work focusses on biotech development, scalable health solutions and business opportunities in underserved regions in the United States, France and low/middle countries such as the Democratic Republic of Congo, Cote d'Ivoire, Afghanistan, Jamaica, Asia, Kenya and India. Consulting to the President of the United States, the US State Department, US Army and internationally, James in 2018 was awarded the President's Medal for promoting social embeddedness. 300 million people live with rare diseases without effective cures. Sustainable solutions require the efficient use of capital to optimize biotechnology companies, maximize impact and minimize suffering.

Philanthropy is valued in French culture. According to the Fondation de France's barometer of French philanthropy, there are 4,650 Funds and Foundations in France in 2023. These structures commit nearly 11 billion euros per year to serve the general interest, an amount that continues to increase every year. Today, more than 30 billion euros in assets are held by these Funds and Foundations. Despite the deep-rooted value of philanthropy in French society, the non-for-profit sector is notoriously complicated in France. This book examines several types of foundations in France, including endowment funds, sheltered foundations, foundations recognized as being of public utility, and corporate foundations. Pros and cons for each are discussed in relation to their mission scope. Overall, understanding these distinctions is important for effective philanthropic strategies and for maximizing societal impact.

Every rare disease begins with a patient and a question: why isn't there a treatment? Too often, the answer isn't scientific, it is financial. The science exists. The will does exist. But the funding pathways don't. For decades, rare disease research has been caught between two worlds: public grants that are too short-term to sustain discovery, and private investment that sees too little market potential to engage. Thousands of promising ideas never leave the lab, not because they failed, but because the funding system did. This book is written to change that. Across the world, funders, patient organizations, and scientists are experimenting with bold, hybrid approaches that blend the discipline of finance with the purpose of medicine. Venture philanthropy, public-private partnerships, social impact bonds, and collaborative consortia are not financial curiosities, they are survival strategies for rare disease innovation. The aim of "Alternate Funding Mechanisms in Rare Diseases" is simple: to make these approaches understandable, usable, and actionable. Whether you lead a foundation, manage a research program, or simply care deeply about someone living with a rare condition, this book shows how to turn financial creativity into measurable impact. ABOUT THE AUTHOR Dr. Levine, President Fondation Ipsen, has three decades of experience in the healthcare sector principally at Mayo Clinic. For the last 6 years he has been President of Fondation Ipsen, an international science foundation focused on biotech innovation in Rare Diseases. A physician and scientist, James has published more than 200 articles, six papers in Science and Nature plus articles in journals such as, the New England Journal of Medicine, Lancet and JAMA. He has written four books published in 19 languages in 37 countries. His business training, focused on entrepreneurship, was from Harvard Business School. With a background in wearable technologies, data gathering and data analytics, and with more than 100 patents and trademarks, Levine helped found 35 companies. He was the Innovator of the Year in the state of Minnesota, the World Trade Fair and NASA. Under the Mayo Clinic NEAT Trademarks, Levine's team delivered scalable health solutions to 72 US corporations. A great deal of James' work focusses on biotech development, scalable health solutions and business opportunities in underserved regions in the United States, France and low/middle countries such as the Democratic Republic of Congo, Cote d'Ivoire, Afghanistan, Jamaica, Asia, Kenya and India. Consulting to the President of the United States, the US State Department, US Army and internationally, James in 2018 was awarded the President's Medal for promoting social embeddedness. 300 million people live with rare diseases without effective cures. Sustainable solutions require the efficient use of capital to optimize biotechnology companies, maximize impact and minimize suffering.

Living with a rare disease is not only a medical experience-it is a human one. It reaches into every part of life: the body that struggles, the mind that questions, the family that hopes, and the community that rallies. This book began with that truth and has followed it through the many ways people find comfort, meaning, and strength when medicine alone is not enough. Across these chapters we have explored how complementary practices-mindfulness, yoga, art, touch, and reflection-can restore balance and dignity. We have met caregivers who hold entire households together, and patients who, despite pain and uncertainty, continue to build lives that are creative, purposeful, and full of courage. The message is simple but profound: well-being is not a luxury or an afterthought. It is part of treatment itself. Every breath of calm, every shared laugh, every moment of understanding between a patient and a caregiver is an act of healing. ABOUT THE AUTHOR A graduate of Cambridge, James A. Levine became a physician by vocation and a writer almost by accident. He is a professor of medicine at the renowned Mayo Clinic in Minnesota, where he lives with his wife and their daughters. It was during a visit to the repugnant Rue des Cages in the Komatipura district of Bombay-where, under dramatic conditions, some of the 1.2 million children prostituted in India are forced to work-that James A. Levine saw a fifteen-year-old girl in a pink sari writing in a blue notebook. From this encounter came "The Blue Notebook", a powerful and unsettling first novel about child prostitution, the new slaves of the twenty-first century. The royalties from sales of The Blue Notebook are donated to the International Centre for Missing and Exploited Children. It was while traveling through emerging countries on behalf of the United Nations that the idea came to him to bear witness to the conditions in which his future heroes grow up and live. If you want a more literary tone-or a tighter, back-cover version-I can tweak the style.